inflect the earpiece in stethoscopes assigned to individual patients, also.

REFERENCE

Itzhak Brook, MD
Georgetown University
Washington, DC

Safety Butterfly Needles for Blood Drawing

To the Editor:
Despite safety recommendations, the increased availability of personal protective equipment, and the implementation of improved disposal systems, high-risk needlestick injuries continue to occur in unacceptably high numbers in healthcare settings.1

Design features of needle devices are relevant to their high injury risk. For example, butterfly-type devices with needle-shielding features to protect against needlestick injuries showed a 25% reduction in needlesticks in a clinical trial.2 Any other risk-reducing design enhancements that can be incorporated into butterfly-type devices should be promoted and evaluated, particularly those intended for blood drawing, because of their disproportionate involvement in the transmission of bloodborne pathogens.

In a recent study on device-specific sharps injuries among health-care workers, of all hollow-bore needles, conventional butterfly needles were associated with the highest injury rate per 100,000 devices.3 This finding is consistent with the high rate of injury from butterfly-type needles documented in the Italian study of occupational exposure to HIV.4

In the above-mentioned study, the highest use of butterfly-type needles was among laboratory phlebotomists. Similarly, in 569 (27%) butterfly-related needlesticks reported in the Italian study on Occupational Risk of HIV—Exposure Prevention Information Network study, the device was used to draw blood, and 176 (31%) of these incidents occurred while putting the butterfly into a disposal container.

These data demonstrate that, in relation to current practice, butterfly-type devices frequently are used for blood drawing, a different procedure than that for which they were designed. We suggest that butterfly-type devices intended for blood drawing should have only a short length of tubing and that the tubing should not be packaged in coils. The effectiveness of these kinds of devices should be evaluated.

REFERENCES

Vincenzo Puro, MD
Giuseppe Ippolito, MD

Vancomycin Use and Monitoring in Pediatric Patients in a Community Hospital

To the Editor:
Before 1988, resistance to vancomycin was rare in gram-positive bacteria. An increase in infection and colonization with vancomycin-resistant enterococci was reported after 1989,1 and the Centers for Disease Control and Prevention (CDC) issued guidelines in 1995 recommending that vancomycin be used to treat only serious infections caused by β-lactam–resistant gram-positive cocci or used in patients with serious allergies to β-lactams.2 We investigated patterns of vancomycin use in pediatric patients at our institution in reference to CDC guidelines.

In this retrospective study, information was abstracted from the vancomycin dispensing log of the pharmacy department on all patients age 18 and younger (patients admitted to the neonatal intensive-care unit were excluded) who received vancomycin between January 1, 1994, and December 31, 1995. Patient's age, admitting diagnosis or symptoms and signs, accompanying illness, location, duration of vancomycin therapy, other antibiotics used, number of serum vancomycin levels obtained, monitoring of blood urea nitrogen and creatinine, number of vancomycin dosages adjusted, development of any adverse reactions, and type, results, and susceptibilities of bacterial cultures were recorded.

During the study period, there were 6,239 admissions, of whom 80 (1.3%) received either parenteral (77 continued on page 301

The SIROH-EPINet is supported by the Italian Ministry of Health-AIDS project. The authors thank Janine Jagger, MPH, PhD, Virginia University, for revising the manuscript and offering her comments; all participants of the SIROH, for data gathering; and the nurses of Lazzaro Spallanzani Hospital, for their useful suggestions.
The Premium Care System Formulated Specifically for Healthcare Personnel Handwashing Around the Clock

PRIMA-KARE™ 0.75% CHG and Lotion

PRIMA-KARE 0.75% CHG offers an excellent data package with efficacy against antibiotic resistant organisms such as MRSA and VRE. PRIMA-KARE Lotion is CHG compatible and will not compromise the residual activity of CHG on skin. Unlike conventional lotions, PRIMA-KARE moisturizes your hands without compromising the residual buildup achieved from washing with PRIMA-KARE 0.75% CHG. Together these products offer a total handcare system to enhance handwashing compliance while maintaining the integrity of healthcare workers' skin.
**TABLE**

**Duration of Vancomycin Administration, Number of Patients Who Received Other Antibiotic(s) Either With or Following Vancomycin Administration, Estimated Costs of Vancomycin Administration, and Serum Drug Monitoring in Three Categories of Patients**

<table>
<thead>
<tr>
<th>Patients Meeting CDC Guidelines</th>
<th>High-Risk Patients</th>
<th>Other Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>22</td>
<td>28</td>
</tr>
<tr>
<td>Days of vancomycin administration, mean (range)</td>
<td>7.7 (1-28)</td>
<td>4.8 (1-28)</td>
</tr>
<tr>
<td>Patients given other antibiotics (%)</td>
<td>14 (53%)</td>
<td>28 (100%)</td>
</tr>
<tr>
<td>Patients given other antibiotics after vancomycin was discontinued (%)</td>
<td>4 (18%)</td>
<td>9 (33%)</td>
</tr>
<tr>
<td>Estimated cost of vancomycin and its administration</td>
<td>$11,870</td>
<td>$9,400</td>
</tr>
<tr>
<td>Estimated cost of serum drug monitoring</td>
<td>$4,435</td>
<td>$5,645</td>
</tr>
</tbody>
</table>

Abbreviation: CDC, Centers for Disease Control and Prevention.

*continued from page 299*

... patients) or oral (3 patients) vancomycin. Of these 80 patients, 23 had a malignancy and a central venous access device, 3 had a ventriculoperitoneal shunt, 7 had either congenital immune deficiency or serious immunological impairment because of immunosuppressive therapy, 19 were hospitalized for surgery or burn, and 28 could not be categorized in any of the above diagnostic groups.

Patients were classified into three treatment groups: group 1, 22 (28%) patients who met CDC guidelines for vancomycin use; group 2, 28 (35%) high-risk patients (febrile neutropenic oncology patients with central venous access device or patients with suspected ventriculoperitoneal shunt infection) for whom vancomycin was prescribed empirically; and group 3, 30 (38%) patients who did not fulfill any of the above criteria. Patients who met the CDC guidelines for vancomycin use included those with bacteremia due to methicillin-resistant Staphylococcus epidermidis (MRSE) or methicillin-resistant *Staphylococcus aureus* (MRSA), suspected bacterial meningitis, severe allergy to penicillin with pneumatocele on chest radiograph, and ampicillin-resistant *Streptococcus faecalis* infection. The duration of vancomycin administration, number of patients who received other antibiotics, estimated cost of vancomycin administration, and drug monitoring is given in the Table.

Thirty-five patients (44%) received vancomycin for less than 4 days, 38 (48%) for 4 to 10 days, and only 7 for greater than 10 days. The pharmacy dosing service monitored vancomycin levels in all patients receiving parenteral vancomycin. The number of changes in the dosage of vancomycin ranged from 0 to 3, with a mean of 0.58 per patient. The average cost of drug level assays was $202 per patient.

In this study, according to CDC guidelines, vancomycin was the appropriate drug in only 22 patients (28%). In 8 (36%) of the 22 patients, treatment with vancomycin was initiated only after culture results were available. Twenty-eight high-risk patients were prescribed vancomycin empirically, following prescribing practices that became common during the past 2 decades because of emergence of methicillin resistance in *S. aureus* and *S. epidermidis*. Vancomycin use in our hospital appears to be similar to the use patterns reported recently from other children’s hospitals or pediatric centers. At our institution, the current incidence of MRSA is 31% and MRSE is 78%. Nevertheless, Pizzo and colleagues have shown that ceftazidime alone is adequate in many settings, because infections caused by *S. epidermidis* often are not severe and do not progress rapidly.

All patients receiving parenteral vancomycin also were monitored for serum drug concentrations. Recently there have been debates in the literature about the usefulness of therapeutic drug monitoring for vancomycin. The majority of patients in our study received vancomycin for a very brief period, and all had normal kidney functions. Therefore, drug level monitoring in many patients may not have been necessary. Continued educational efforts are necessary to familiarize healthcare providers with the CDC guidelines regarding appropriate use of vancomycin treatment in all settings and appropriate guidelines for drug-level monitoring need to be established for pediatric patients.

**REFERENCES**


Ozlem Kahyaoglu, MD
Mustafa Akpinar, MD
Brian Nolan, MD
Susumu Inoue, MD
George Zureikat, MD
Ashir Kumar, MD
Michigan State University
Flint, Michigan